print_label | resize_label

A TREATMENT FOR ADULTS WITH TYPE 2 DIABETES MELLITUS, IN ADDITION TO DIET AND EXERCISE

DEMONSTRATED REDUCTIONS IN A1C LEVELS WITH KOMBIGLYZE XR

CLINICAL TRIALS

INITIAL DRUG THERAPY

Saxagliptin 5 mg and metformin IR as initial therapy, compared with metformin IR monotherapy in patients who are treatment-naïve1,2

ADD-ON COMBINATION THERAPY

Saxagliptin 5 mg + metformin IR compared with metformin IR + placebo in patients who are uncontrolled on metformin monotherapy1,3

There have been no clinical efficacy or safety studies conducted with KOMBIGLYZE XR. Relative bioavailability studies between KOMBIGLYZE XR and coadministered saxagliptin and metformin IR tablets have not been conducted. Bioequivalence was demonstrated in healthy adults between KOMBIGLYZE XR and saxagliptin plus metformin XR as separate tablets.